Biocon, Ltd.
http://www.biocon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biocon, Ltd.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
Biocon And Biomm Team Up In Brazil On Ozempic Rival – With Potential Near-Term Launch
India’s Biocon Limited has struck an exclusive deal for a generic version of semaglutide in Brazil with local player Biomm. And a recent court ruling means that launch could come sooner rather than later for the Ozempic rival.
Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets
With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.
Biocon And Zentiva Hail Milestone Liraglutide Approval In UK
Biocon and Zentiva have celebrated the “first generic liraglutide approved in a major regulated/ICH market” after an endorsement from the UK’s MHRA.
Company Information
- Industry
- Biotechnology
- Distributors
- Medical Devices
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Biocon Sdn Bhd.
- Biocon Limited
- Biocon Biologics India Ltd
- Bicara Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice